ABl Europe is a pure-play GMP certified viral vector CDMO. ABL’s experts are producing and testing today’s leading oncolytic viruses, gene therapies, immunotherapies and viral vaccines.

ACOBIOM is a biotech company specialized in the discovery of new biomarkers and the development of diagnostics tests focused on precision medicine applications (oncology). Acobiom notably developed “GemciTest™,” a non invasive blood test, which is the 1st diagnostic for the prediction of treatment response in pancreatic cancer. Acobiom developed many capabilities in the bioinformatics analysis of gene expression and in the identification of RNA biomarkers that are specific to the studied pathology or biological question. Our scientific team is using a unique and patented technological Omic platform based on New Generation Sequencing (NGS) and real-time PCR associated with proprietary bioinformatics and biostatistics tools.

Aenitis develops innovative patented devices for the continuous handling, without contact or pressure, of suspended cells by the use of acoustic radiation forces (called acoustophoresis). Aenitis focuses on the development and sales of medical devices and lab instruments addressing bioproduction preparation issues in cell and gene therapy.

Specialized in genomic analysis, BIOMNIGENE is able to validate the effect, impact of a product on life. We can answer to medical, environmental and industrial (pharmaceutical, agro-food, cosmetics) issues to such as : - Intestinal, skin, vaginal, lung, soil microbiomes analysis (Metagenomic, metatranscricptomic, WGS…) - Identification, quantification authentication of bacterial species; - Genotyping - Antibody sequencing and safeguarding of hybridoma lines of special interest; - Construction of recombinant plasmids - Improvement and/or development of advanced experimental protocols - Project advice... We provide a stool sampling kit for microbiome analysis. BIOMNIGENE works in compliance with Good Laboratory Practice

AP-HP MEARY Center for Cell and Gene Therapy is among the leaders in the manufacturing of ATMPs, offering cutting-edge expertise to clinicians, research teams, as well as industrial partners for the support and execution of their cell, tissue, and gene therapy clinical trials.

University hospital of Rouen Normandy advanced therapy facility NORMAcell

CILcare is the world-leading R&D services company specialized in hearing disorders. Based in Montpellier, Boston, Paris and Copenhagen, CILcare has become the one-stop partner for pharmaceutical industries, biotechs and medtechs developing novel therapies for people with hearing and otic disorders. Hearing loss is recognized as a major global health concern with an increasing worldwide prevalence and the absence of approved drug on the market. CILcare’s mission is to make hearing a priority and give hope to the 466 million people worldwide waiting for effective solutions to treat hearing impairment.

The EFS is the sole player in transfusion in France. In addition to its activities of collection, preparation, qualification and distribution of Labile Blood Products (PSL), EFS is a major player in cell and tissue therapies and in the design and production of MTI. Its CDMO activity offers clinical batch production capacities on several platforms.

Eukarÿs develops synthetic gene therapies, a novel non-viral therapeutic platform. Synthetic gene therapy relies on Eukarÿs’ proprietary technologies (i.e. C3P3 – the first ever artificial system able to synthesize autonomously the messenger RNA in cells – and Möbius – an technology to produce the therapeutic synthetic DNA used for therapeutics). Synthetic gene therapy is designed to resolve the main obstacles that other approaches must face, i.e. safety, tolerance, efficacy, vectorization immunogenicity, low production costs and can be adapted to most human disorders. Eukarÿs current pipeline is for liver diseases, with the most advanced product currently at CMC before non-regulatory preclinical phase. The same technologies were recently adapted to vaccination gene vaccination, with a special focus on Covid-19/SARS-Cov-2, with the objective to develop cost-effective and potent vaccines.

Firalis is a biotechnology company with a mission to improve disease outcome, therapeutic decisions and generate savings in healthcare through biomarker discovery, development and regulatory qualification that ultimately leads to biomarker-based diagnostics. Firalis is active in the field of drug safety, cardiovascular, inflammatory, neurodegenerative and autoimmune diseases.

Created in 1990 by AFM-TELETHON, Genethon is fully dedicated to the design and development of gene therapy treatments for rare diseases. Its objective is to provide these innovative treatments to patients affected with rare disorders. Genethon is developing therapies for rare neuromuscular diseases, liver diseases and immune system or blood disorders.

HARMONIC PHARMA is a deeptech providing the pharmaceutical, chemistry, biotechnology, cosmetics and nutraceutical industry with customized services during compound development projects. HARMONIC PHARMA has developped In Silico predictions tools tailored to profile a compound activity and/or toxicity.

IPRASENSE provides cell analysers for real-time monitoring of cell cultures. Our SME, based in the Montpellier area, relies on expertise in holographic imaging acquired with CEA Leti since its creation in 2013. Our instruments focus on both the academic research and the pharmaceutical industry from the cell line development stages up to the bioproduction in GMP environment.

Keyrus Life Science is a unique Connected Clinical Research & Development Organization. We believe that it is only by making sense of data that mankind can solve the major health challenges it faces. Keyrus Life Science helps connect industry expertise, Life Data Sciences and Digital Enablement to fully leverage both Clinical Research ecosystems and Real-World Evidence/RWE in healthcare, thus enhancing the reliability, innovative capacity, agility, and, above all, speed of execution of Clinical Research activities.

With more than 40 years of experience in cryopreservation, quality and regulatory affairs, LinBox can propose solutions related to biobanks and tissues and cells grafts’ cryopreservation.

Lysogene is a biopharmaceutical gene therapy company, founded in 2009, with lead programs in neurodegenerative lysosomal storage disorders that affect children. Lysogene uses recombinant adeno-associated virus (AAV) that specifically targets neural cells and is administered directly into the brain or cerebrospinal fluid (CSF).

Medesis Pharma is a Pharmaceutical Biotechnology company whose products and programs in development are based on drug delivery technology allowing, after oral administration, a plasma transport protected in HDL lipoproteins and an intra-cellular delivery of water-soluble pharmaceutical active ingredients: metal ions, as well as biological molecules such as oligonucleotides and peptides, with a passage of BBB.

Naobios is a CDMO based in Nantes with over 15 Years Experience offering a comprehensive set of services to effectively support customers worldwide with Process Development, GMP Manufacturing and testing of viral vaccines and viral vectors candidates in preclinical and clinical development.

We are specialists in autoimmunity, inflammatory diseases and oncology, providing tailored cell-based and immunoassays and dedicated laboratory solutions for biopharma companies and clinical diagnostic labs through our worldwide partner network. Simply put, we can provide the answers that our customers need throughout the entire drug development value chain – from early discovery through the clinical phases until the bioanalytical support for batch releases (cell-based potency assays)

The strength of our distribution activity through the pan-European branches of our group, lies in our longstanding relationships with our suppliers. This allows us to provide first-rate service and to be the reliable source for reagents critical to our customers’ research and product development. In parallel, access to a broad selection of ethical sources, including collections of biological samples and primary cells, enables us to perform in vitro assays for understanding mechanisms of actions (MOA) and demonstrating proofs of concepts (POC) with a short turnaround time.

Thermo Fisher Scientific is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer.

Yposkesi is one of the largest Contract Development & Manufacturing Organizations (CDMO) in Europe for gene therapy viral vector manufacturing and proposes an integrated service offering: bioprocess development (upstream and downstream processing), analytical development, small/pilot to large-scale production, GMP manufacturing of clinical batches of lentiviral and AAV (Adeno-Associated Virus) vectors and regulatory support, commercial batches to come in 2021. Its current 50,000ft2 state-of-the-art facility houses four independent manufacturing suites for bulk drug substance and two fill & finish suites. It is doubling this footprint to 100,000ft2 to expand its capacity to support the future large scale needs of its clients by the end of 2021.